On this page
Research Article | Open Access
Volume 14 2022 | .
EXPERIENCE WITH LEVOCARNITINE IN THE COMPLEX TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN WITH MYOCARDITIS
Kardzhavova Gulnoza Abilkasimovna
Pages: 550-555
Abstract
Pneumonia in children is one of the urgent problems of pediatrics, which is determined by the continuing high incidence and severe prognosis, especially in young children. The aim of the study was to evaluate the effectiveness and use of levocarnitine in the treatment and prevention of myocarditis in children. We examined 150 children aged 1 to 7 years with pneumonia, which we divided into 4 groups. The results proved that against the background of community-acquired pneumonia in children, all the symptoms of acute heart failure are masked, the cause of which in most cases is acute coronary insufficiency, a change in the heart muscle in this pathology in children increases the risk of severe unwanted complications from the heart, which should be included in the future in complex therapy, the drug levocarnitine.
Keywords
acute myocarditis, community-acquired pneumonia, levocarnitine, children.
PDF
114
Views
54
Downloads